氯雷他定联合阿伐斯汀治疗慢性难治性荨麻疹的效果及安全性分析

目的 探讨氯雷他定联合阿伐斯汀治疗慢性难治性荨麻疹的效果及安全性。方法 选择2019年1月至2020年6月本院接收的慢性难治性荨麻疹患者85例,采用随机数字表法将其分为对照组(42例)和观察组(43例)。对照组采用阿伐斯汀胶囊口服治疗,在对照组基础上,观察组采用氯雷他定片口服治疗,治疗4周后,比较两组临床疗效、实验室相关指标白细胞(WBC)、5-羟色胺(5-HT)、血清免疫球蛋白(IgE)]、安全性。结果 观察组临床总有效率(95.35%)高于对照组(78.57%),差异有统计学意义(χ2=5.308,P=0.021);治疗4周后,观察组5-HT水平(127.65±8.61)μg/L高于对照组的(104.52±9.32)μg/L,IgE水平(57.41±7.53)IU/mL、WBC水平(9.20±1.95)g/L低于对照组的(72.26±8.40)IU/mL、(11.31±2.04)g/L,差异有统计学意义(t=11.889、8.587、4.875,P均=0.000);观察组不良反应发生率(11.63%)与对照组(7.14%)对比,差异无统计学意义(χ2=0.501,P=0.713)。结论 予以慢性难治性荨麻疹患者氯雷他定联合阿伐斯汀治疗效果确切,可改善患者实验室相关指标,且未明显增加不良反应,安全性较高。

Efficacy and safety of loratadine combined with avastin in treatment of chronic refractory urticaria

Objective To investigate the efficacy and safety of loratadine combined with avastin in the treatment of chronic refractory urticaria. Methods A total of 85 patients with chronic refractory urticaria received in our hospital from January 2019 to June 2020 were randomly divided into a control group (42 cases) and an observation group (43 cases) according to the random number table method. The control group was treated with avastin capsule orally. On the basis of the control group, the observation group was treated with loratadine tablets orally. After 4 weeks of the treatment, the clinical efficacy, laboratory related indexes and safety of the two groups were compared. Results The total clinical effective rate of the observation group (95.35%) was higher than that of the control group (78.57%) (χ2=5.308, P=0.021). After 4 weeks of treatment, the level of 5-HT in the observation group was higher than that in the control group, and the levels of IgE and WBC (9.20±1.95) ×109/L were lower than those in the control group, and the difference was statistically significant (t=11.889, 8.587, 4.875, P=0.000). There was no significant difference in the incidence of adverse reactions between the observation group (11.63%) and the control group (7.14%) (χ2=0.501, P=0.713). Conclusion Loratadine combined with avastin is effective in the treatment of chronic refractory urticaria, which can improve the relevant laboratory indicators of the patients, and has no obvious increase of adverse reactions, with high safety.